Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic

Status Recruiting

Clinical Trial Summary

The research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.

Clinical Trial Description

Neurosurgical resection of a brain metastasis in patients with a diagnosis of cancer may be indicated however the recurrence rate approximates 50% and adjuvant radiotherapy is standard. Single fraction postoperative stereotactic radiosurgery (SRS) has been widely adopted as a standard therapy as it achieves equivalent survival and prevents loss of neurocognitive function as compared with whole brain radiotherapy and improves cavity local control rates as compared with observation. Hypofractionated stereotactic radiotherapy in 3 to 5 fractions (hfSRT) is also used in the postoperative setting. Nodular leptomeningeal disease (nLMD) is a recognised pattern of failure after postoperative SRS and hfSRT. A 16.9% incidence of nodular LMD was seen after surgery and a similar incidence of 11%-28%is reported following postoperative SRS in retrospective series. These data suggest that postoperative SRS/hfSRT have no significant effect on the development of LMD following surgery. The incidence of LMD following single fraction preoperative SRS is only 6.1% according to the largest retrospective series. Preoperative SRS takes advantage of the easier delineation of an intact BM and sterilizes tumor cells disseminated at surgery. Side effects are minimized by a smaller planning margin, a dose reduction and resection of the irradiated volume. In addition, there is no delay to systemic therapy due to wound healing/complications. Furthermore, a single fraction offers patient convenience. This trial will randomise and compare intracranial outcomes between single fraction preoperative SRS and 5 fraction postoperative hFSRT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05124236
Study type	Interventional
Source	Kantonsspital Aarau
Contact	Susanne Rogers, MD PhD
Phone	+41 62 838 5726
Email	Susanne.rogers@ksa.ch
Status	Recruiting
Phase	N/A
Start date	July 29, 2022
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05428852` - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases	N/A
Recruiting	`NCT05559853` - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting	`NCT05689619` - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)	N/A
Recruiting	`NCT04197297` - Brain Imaging Biomarkers in Patients With Brain Metastasis	Phase 2
Recruiting	`NCT04397978` - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated	`NCT04434560` - Neoadjuvant Immunotherapy in Brain Metastases	Phase 2
Active, not recruiting	`NCT05095766` - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting	`NCT05012254` - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases	Phase 2
Recruiting	`NCT05789589` - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT06280300` - Multi-disciplinary Care for Brain Metastases	N/A
Recruiting	`NCT06047379` - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Phase 1/Phase 2
Completed	`NCT03896555` - Intrafractional Head Movement During Radiosurgery
Terminated	`NCT03789149` - Focal Intraoperative Radiotherapy of Brain Metastases	Phase 2
Recruiting	`NCT04343157` - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases	Phase 2
Recruiting	`NCT04711824` - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT05793489` - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin	N/A
Recruiting	`NCT04461418` - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases	Phase 2
Recruiting	`NCT03818386` - Radiotherapy of Multiple Brain Metastases Using AGuIX®	Phase 2
Active, not recruiting	`NCT05087095` - Managing Distress in Malignant Brain Cancer	N/A
Recruiting	`NCT04396717` - Safety Study of Pritumumab in Brain Cancer	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases — PREOP-2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms